Drug Profile

Recombinant human MG53 protein - TRIM-edicine

Alternative Names: MG53; Mitsugumin53; Recombinant Mitsugumin53; rhMG53; TRIM72

Latest Information Update: 28 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator TRIM-edicine
Class Anti-ischaemics; Recombinant proteins
Mechanism of Action Cell membrane permeability enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Ischaemia
No development reported Muscular dystrophies

Most Recent Events

28 Jan 2024 No recent reports of development identified for preclinical development in Muscular-dystrophies in USA (Parenteral)
03 Jan 2022 Preclinical development is still ongoing for Muscular dystrophies in USA (TRIM-edicine pipeline, January 2022)
13 Nov 2021 Preclinical trials in Ischaemia in USA (Parenteral) before November 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com